Zanidatamab and chemo before and after surgery for HER2+ stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests adding zanidatamab (an antibody targeting HER2) to standard chemotherapy before and after surgery for operable HER2-positive stomach or esophagus cancer. It aims to see if this combination improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive adenocarcinoma of the stomach, esophagus, or gastroesophageal junction.
- Your cancer is localized and can be surgically removed (not spread to other organs).
- You are in good physical condition (ECOG 0 or 1).
- You have adequate kidney, liver, and heart function.
- You are at least 18 years old and agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes people with advanced HER2-positive stomach or esophageal cancer who are starting a treatment that includes zanidatamab. It collects information about their experiences and quality of life during treatment.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
This trial tests a new drug called zanidatamab combined with standard chemotherapy before surgery for HER2-positive stomach or gastroesophageal junction cancer. It aims to shrink the tumor and improve outcomes.
This trial tests a new targeted drug called zanidatamab given with standard chemotherapy before surgery for HER2-positive stomach or gastroesophageal junction cancer. It aims to shrink the tumor enough to allow successful removal, either for cancers that were initially too advanced for surgery or for those with high-risk features.
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
This trial tests if the drug zanidatamab, given before surgery, can help treat colon or rectal cancer that has a specific marker called HER2. The goal is to see if this approach can shrink tumors and improve outcomes for people whose cancer has not spread to other parts of the body.
Hear when a new GastroEsophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.